Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

Original Article

T.K. Choueiri, T. Powles, L. Albiges, M. Burotto, C. Szczylik, B. Zurawski, E.Y. Ruiz, M. Maruzzo, A.S. Zaizar, L.E. Fein, F.A. Schutz, D.Y. Heng, F. Wang, F. Mataveli, Y.-L. Chang, M.v.K. Losio, C. Suarez, and R.J. Motzer

N Engl J Med 2023;388:1767-1778

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
05/10/2023
Course expires: 
05/11/2025
Take course

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Take course